A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine against Plasmodium falciparum Malaria

JA Stoute, M Slaoui, DG Heppner… - … England Journal of …, 1997 - Mass Medical Soc
Background The candidate vaccines against malaria are poorly immunogenic and thus have
been ineffective in preventing infection. We developed a vaccine based on the
circumsporozoite protein of Plasmodium falciparum that incorporates adjuvants selected to …

Glycoprotein-D–adjuvant vaccine to prevent genital herpes

…, S Sacks, S Tyring, FY Aoki, M Slaoui… - … England Journal of …, 2002 - Mass Medical Soc
Background An effective prophylactic vaccine would help control the spread of genital
herpes. Methods We conducted two double-blind, randomized trials of a herpes simplex
virus type 2 (HSV-2) glycoprotein-D–subunit vaccine with alum and 3-O-deacylated …

Drug discovery: a jump-start for electroceuticals

K Famm, B Litt, KJ Tracey, ES Boyden, M Slaoui - Nature, 2013 - nature.com
Already, devices that harness electrical impulses are used to treat disease. Pacemakers and
defibrillators save millions of lives each year; deep-brain stimulation dramatically improves
the quality of life for people with Parkinson's disease and depress ion; sacral-nerve …

Potent induction of focused Th1-type cellular and humoral immune responses by RTS, S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine

…, KL Flanagan, C Carton, M Slaoui… - The Journal of …, 1999 - academic.oup.com
Abstract The RTS, S/SBAS2 vaccine confers sterile protection against Plasmodium
falciparum sporozoite challenge. The mechanisms underlying this are of great interest, yet
little is known about the immune effector mechanisms induced by this vaccine. The immune …

Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A

P Hauser, P Voet, M Slaoui… - US Patent …, 1998 - Google Patents
3-O-deacylated monophosphoryl lipid A (or 3 De-O-acylated monophosphoryl lipid A) has formerly
been termed 3D-MPL or d3-MPL to indicate that position 3 of the reducing end glucosamine
is de-O-acylated. For preparation, see GB 2 220 211 A. Chemically it is a mixture of 3-deacylated …

Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs

…, DI Bernstein, MG Myers, M Slaoui… - The Journal of …, 2003 - academic.oup.com
In two recent clinical trials, a vaccine containing herpes simplex virus (HSV) type 2
glycoprotein D (gD2) and a novel adjuvant AS04 comprising alum (Al) and 3-deactylated
monophosphoryl lipid A (3-dMPL) afforded HSV-seronegative women significant protection …

Seroprevalence of herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents

…, LR Stanberry, FM Biro, M Slaoui… - Clinical infectious …, 1997 - academic.oup.com
We determined the prevalence of herpes simplex virus (HSV) and cytomegalovirus (CMV)
antibodies in a cohort of adolescents 12 to 22 years of age in anticipation of the
development of vaccines to control HSV and CMV infections. For the overall study …

Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs

…, FJ Bravo, MR Schleiss, M Slaoui… - Journal of Infectious …, 1995 - academic.oup.com
Cytomegalovirus (CMV) is the most common congenital viral infection, but little is known
about the protective immune mechanisms. The guinea pig (gp) model of congenital CMV
was used to evaluate the effects of passive antibody given to pregnant dams on pup …

Vaccination with recombinant vaccinia viruses expressing ICP27 induces protective immunity against herpes simplex virus through CD4+ Th1+ T cells.

…, M Dewerchin, C Molitor, D Gheysen, M Slaoui… - Journal of …, 1995 - Am Soc Microbiol
This study was designed to evaluate the efficacy and mechanisms of protection mediated by
recombinant vaccinia viruses encoding immediate-early (IE) proteins of herpes simplex virus
type 2 (HSV-2). Three mouse strains were immunized against the IE proteins ICP27, ICP0 …

Adjuvants influence the quantitative and qualitative immune response in BALBc mice immunized with respiratory syncytial virus FG subunit vaccine

KM Neuzil, JE Johnson, YW Tang, JP Prieels, M Slaoui… - Vaccine, 1997 - Elsevier
The ability of monophosphoryl lipid A (MPL), QS-21, and alum to alter the immunologic
response to immunization with respiratory syncytial virus a chimeric FG construct (FG)
subunit vaccine was examined in BALB c mice. FG MPL, FG/alum, and FG/MPL/QS-21 …